Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

Sheth, Anandi N.; Patel, Pragna; Peters, Philip J.

doi:10.1007/s11904-011-0086-4

Cited by 38 publications

(29 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8][9][10] The clinical presentation of the 2009 H1N1 infection in HIV-infected individuals showed similar outcomes in well-controlled highly active antiretroviral therapy (HAART)-treated HIV patients and in healthy donors. 11,12 In contrast, patients with advanced HIV disease experienced severe 2009 H1N1 infection and increased mortality.…”

Section: Introductionmentioning

confidence: 99%

Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients

Agrati

Gioia

Castilletti

et al. 2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients

Agrati

Gioia

Castilletti

et al. 2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

“…In fact, cases of severe complications with onset of pneumonia that led to hospitalization and that, in one case, required oxygen supplementation, were detected only in HIV-negative patients. This is in apparent contrast with previous findings, where no remarkable differences in clinical outcomes were observed in HIV-positive patients compared to HIV-negative subjects [18,19]. In a study by Peters et al, 911 subjects were analyzed in three separate cohorts, which included HIV+ patients with CD4 counts below 200, with half taking ART.…”

Section: Discussionmentioning

confidence: 74%

Immune response to influenza A(H1N1)v in HIV-infected patients

Sansonetti

Sali

Fabbiani

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: HIV infection is considered a risk factor for severe outcomes of influenza A(H1N1)v infection. However, data on immune response against influenza A(H1N1)v virus in HIV-infected patients are lacking. Methodology: Data from seven HIV-positive and 14 HIV-negative patients infected with A(H1N1)v and from 23 HIV-positive and six HIV-negative asymptomatic controls were analyzed to evaluate the clinical picture, A(H1N1)v viral shedding, and the immune response against the virus. Results: Patients displayed mainly upper respiratory tract diseases (57.1%), while pneumonia was diagnosed only in HIV-negative patients (23.8% of subjects, of which 4.8% required intensive care unit admission). At day seven, 29% of HIV-infected patients were still positive for A(H1N1)v by RT-PCR on nasopharyngeal swabs. Interestingly, a persistence of CXCL10 secretion at high level and lower IL-6 levels was observed in HIV-positive subjects. The geometric mean haemagglutination inhibition titer (HI-GMT) and anti-influenza IgM levels were lower in HIV-positive individuals while anti-influenza IgG levels remained similar in the two groups. Conclusions: The immune impairment due to HIV infection could affect A(H1N1)v clearance and could lead to a lower antibody response and a persistent secretion of CXCL10 at high levels. However, the lower IL-6 secretion and treatment with highly active antiretroviral therapy (HAART) could result in a milder clinical picture.

show abstract

“…Effective ART reduces the rates of hospitalisations and mortality, although the risk of severe outcomes remains comparable to that of other high‐risk groups for which annual influenza vaccination is recommended . In the recent 2009 A/H1N1 pandemic, HIV‐positive adults with advanced immunosuppression or co‐morbid conditions were found to be at an increased risk of influenza‐related complications .…”

Section: Influenzamentioning

confidence: 99%